Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12318362

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12318401

Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

The Regents of the University of California · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12318413

Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

The Board of Regents of the University of Texas System · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310996

Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

The Board of Regents of the University of Texas System · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12311030

Antibody-sting agonist conjugates and their use in immunotherapy

granted patent

US 12303551

Cellular immunotherapy compositions and uses thereof

Cero Therapeutics Holdings, Inc. · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297447

Gene therapy for juvenile Batten disease

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297509

Biomarkers for predicting tumor response to and toxicity of immunotherapy

MIRA DX, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12285496

Gene therapy for haploinsufficiency

The Regents of the University of California · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280140

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunot

Iovance Biotherapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12275955

Combining iPSC derived effector cell types for immunotherapy use

Fate Therapeutics, Inc. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-i

Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12247206

Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239712

Combination therapy for the treatment of liver disease

GALMED RESEARCH AND DEVELOPMENT LTD · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12233103

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230378

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226434

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230364

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burde

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230379

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12228582

Method and apparatus for testing near infrared-photoimmunotherapy treatment

The United States of America as Represented By The Secretary of the Department of Health and Human · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220420

Combination therapy for cancer treatment

Galera Labs, LLC · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220389

Combination therapy for the treatment of tinnitus and other medical conditions

The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12214218

Perfusion modulated tumor dose sculpting with single dose radiotherapy

FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted